ALKS Stock Recent News
ALKS LATEST HEADLINES
Alkermes' (ALKS) earnings and revenues outpace estimates in the fourth quarter of 2023. Strong growth in proprietary products drives year-over-year revenues.
Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The latest trading day saw Alkermes (ALKS) settling at $26.70, representing a -1.26% change from its previous close.
The quest for prime biotech stocks for gains will always be relevant. Moreover, 2024 promises a surge in technology and science, positioning biotech firms at the forefront of novel medical breakthroughs.
The latest trading day saw Alkermes (ALKS) settling at $26.94, representing a -0.41% change from its previous close.
Looking for pharma stocks to buy in February 2024? The pharmaceutical industry has always drawn a big crowd of investors.
Alkermes (ALKS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Alkermes (ALKS) closed the most recent trading day at $27.74, moving -1% from the previous trading session.
Alkermes (ALKS) reachead $27.92 at the closing of the latest trading day, reflecting a +1.34% change compared to its last close.